Press Releases

Filter between ad hoc announcements and corporate releases
Date	Title
29.10.2024	Evolva Holding AG publishes half-year report 2024 and IFRS annual report 2023 AD HOC
15.07.2024	Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 LR; IFRS financial statements for 2023 and half-year 2024 to be published by 31 October 2024 AD HOC
12.04.2024	Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected AD HOC
25.03.2024	Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules AD HOC
22.03.2024	Evolva Holding in liquidation SA publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports positive purchase price adjustment of CHF 1,929,000 under SPA AD HOC
07.03.2024	Shareholder Nice & Green SA requests 3 agenda items to be included in the agenda of the upcoming Annual General Meeting; shareholder Pegasus Global Opportunity Fund Ltd crosses 10% threshold AD HOC
28.12.2023	Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023
21.12.2023	Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting
30.11.2023	Evolva convenes extraordinary general meeting (EGM) for 21 December 2023 to approve the sale of Evolva AG to Lallemand Inc. AD HOC
21.11.2023	Evolva enters into an agreement to sell its operations to Lallemand, securing the best possible outcome for the company and its stakeholders AD HOC
14.11.2023	Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam
28.09.2023	Evolva and LEHVOSS sign agreement for distribution of Veri-teTM Resveratrol in over a dozen European countries AD HOC
13.09.2023	Evolva and Nice & Green agree on improvements to financing agreement AD HOC
06.09.2023	Evolva receives approval for Veri-teTM Resveratrol in Thailand
24.08.2023	Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023
24.08.2023	Evolva with good business momentum and significant progress in profitability in 1H 2023, despite major financing challenges AD HOC
28.07.2023	Evolva Holding SA: Evolva convenes extraordinary general meeting (EGM) for 24 August 2023 to secure financing until end of the year AD HOC
25.07.2023	Evolva receives approval for Veri-teTM Resveratrol in Taiwan
26.06.2023	Evolva Holding SA: Evolva signs agreement with Nice & Green to secure financing at least until the end of 2023, continues to pursue strategic alternatives AD HOC
14.06.2023	Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance AD HOC
05.05.2023	Evolva signs multi-year agreement with leading CMO partner to enable supply of Vanillin to global F&F customer of around CHF 35 million until 2026 AD HOC
24.04.2023	Evolva publishes timeline of the Reverse Stock Split
18.04.2023	Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
28.03.2023	Evolva goes Responsible Care at in-cosmetics 2023
24.03.2023	Evolva publishes agenda for 2023 Annual General Meeting AD HOC
09.03.2023	Evolva delivers accelerated revenue growth of 57% in 2022 and substantially improved profitability profile AD HOC
06.03.2023	Evolva partners with Grace Breeding to replace chemical fertilizers with nature-based alternative AD HOC
11.01.2023	Evolva delivers strong results with 57% revenue growth and increasing margins AD HOC
14.12.2022	Evolva launches its Natural Nootkatone
12.12.2022	Evolva statement to SER communication
29.11.2022	Evolva: Update on activities to boost Resveratrol
10.11.2022	Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil
21.10.2022	Evolva receives grant from US CDC in the amount of USD 540,000
11.10.2022	Evolva’s NootkaSHIELDTM insect repellent approved in Hong Kong
06.10.2022	Evolva business update: Continued good business momentum
25.08.2022	Evolva with record half-yearly sales and new mid-term plan AD HOC
23.08.2022	Evolva statement to SER communication
26.07.2022	Evolva with strong business momentum in 1H 2022, announcing targets of mid-term plan AD HOC
24.05.2022	Evolva successfully placed shares from authorized capital, raising CHF 6.3 million AD HOC
19.05.2022	Evolva business update: On track to reach 2022 guidance AD HOC
12.05.2022	Evolva signs distribution agreement for its Veri-teTM Resveratrol for dietary supplements in Brazil AD HOC
05.05.2022	Evolva shareholders approve all proposed resolutions at the Annual General Meeting 2022
20.04.2022	Evolva achieves important product-related milestones with global customer, triggering revenues of more than 20% of FY21 total revenues AD HOC
07.04.2022	Evolva’s AGM postponed to May 5, 2022 / agenda remains unchanged AD HOC
22.03.2022	Evolva’s Board of Directors intends to further strengthen its expertise at upcoming AGM and proposes, among others, the following agenda items: AD HOC
10.03.2022	Evolva grew product-related revenue by 40% in 2021 AD HOC
28.02.2022	Carsten Däweritz remains CFO of Evolva AD HOC
08.02.2022	Evolva appoints Christian Wichert as new CEO to boost growth strategy and enter its next phase of development and commercialization AD HOC
27.12.2021	Evolva secures additional financing lines to accelerate its growth AD HOC
30.11.2021	Evolva announces private placement of 63.8m shares to VERAISON raising gross proceeds of CHF 7.5m and CFO departure AD HOC
27.09.2021	Evolva issued 40’000’000 shares out of authorized capital AD HOC
26.08.2021	Evolva accelerated revenue growth to 60% and expects gross profit to be positive from Q4, 2021 AD HOC
17.05.2021	Evolva secures additional funding for future growth AD HOC
21.04.2021	Evolva Q1 2021 Trading Update AD HOC
08.04.2021	Evolva shareholders approve all proposed resolutions at the Annual General Meeting 2021 AD HOC
24.03.2021	Evolva announces new Chief Financial Officer AD HOC
16.03.2021	Evolva publishes agenda for 2021 Annual General Meeting AD HOC
02.03.2021	Evolva announces Chief Financial Officer to depart AD HOC
25.02.2021	Evolva reports Full Year Results for 2020, with significant increase in customer demand for Health Ingredients and product expansion AD HOC
20.01.2021	Evolva launches L-arabinose, a natural sugar blocker and reducing sugar AD HOC